These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20959823)

  • 1. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
    Watanabe T; Nagase K; Chosa M; Tobinai K
    Br J Cancer; 2010 Nov; 103(10):1580-7. PubMed ID: 20959823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
    Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
    Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
    Nakano A; Abe M; Oda A; Amou H; Hiasa M; Nakamura S; Miki H; Harada T; Fujii S; Kagawa K; Takeuchi K; Watanabe T; Ozaki S; Matsumoto T
    Int J Hematol; 2011 Jun; 93(6):727-735. PubMed ID: 21526377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
    Peron M; Bonvini P; Rosolen A
    BMC Cancer; 2012 Jun; 12():233. PubMed ID: 22691173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
    Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
    Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
    Kimura T; Uesugi M; Takase K; Miyamoto N; Sawada K
    Toxicol Appl Pharmacol; 2017 Aug; 329():282-292. PubMed ID: 28624441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
    Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
    Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity.
    Wu Z; Yan W; Wang K; Xu G; Zhu D; Li X; Wang H; Yang M; Zhang X; Wu J
    Arch Toxicol; 2023 May; 97(5):1385-1396. PubMed ID: 36826473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
    Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
    Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
    Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
    Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
    Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimyeloma activity of heat shock protein-90 inhibition.
    Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
    Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
    Richardson PG; Badros AZ; Jagannath S; Tarantolo S; Wolf JL; Albitar M; Berman D; Messina M; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):428-37. PubMed ID: 20618338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
    Shin YK; Jang SY; Lee HK; Jung J; Suh DJ; Seo SY; Park HT
    Glia; 2010 Dec; 58(16):1961-76. PubMed ID: 20830808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
    Mitsiades CS; Hideshima T; Chauhan D; McMillin DW; Klippel S; Laubach JP; Munshi NC; Anderson KC; Richardson PG
    Semin Hematol; 2009 Apr; 46(2):166-75. PubMed ID: 19389500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanespimycin as antitumor therapy.
    Dimopoulos MA; Mitsiades CS; Anderson KC; Richardson PG
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):17-22. PubMed ID: 21454186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
    Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.